Last $2.93 USD
Change Today 0.00 / 0.00%
Volume 118.3K
PSTI On Other Exchanges
Tel Aviv
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $4.63
52 Week Low
07/10/14 - $2.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

pluristem therapeutics inc (PSTI) Related Businessweek News

No Related Businessweek News Found

pluristem therapeutics inc (PSTI) Details

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company. It is engaged in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of local and systemic diseases. The company’s PLX (PLacental eXpanded) cells function as a drug delivery platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. PLX cells are grown using proprietary three-dimensional micro-environment technology that produces an off-the-shelf products. It develops PLX-PAD cells, which are in Phase-II clinical trials for use in treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases; and PLX-RAD cells are used for acute radiation syndrome treatment. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary artery hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

142 Employees
Last Reported Date: 09/11/13
Founded in 2001

pluristem therapeutics inc (PSTI) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $544.2K
President and Chief Operating Officer
Total Annual Compensation: $326.3K
Compensation as of Fiscal Year 2013.

pluristem therapeutics inc (PSTI) Key Developments

Pluristem Therapeutics, Inc. Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial

Pluristem Therapeutics Inc. announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). Patient screening is now underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial. The trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients. In May 2014, Pluristem received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) to use PLX cells in South Korean trials.

Pluristem Therapeutics, Inc. Presents at Barclays Select Series 2014: Israel Biotech/Medtech Corporate Day, May-29-2014

Pluristem Therapeutics, Inc. Presents at Barclays Select Series 2014: Israel Biotech/Medtech Corporate Day, May-29-2014 . Venue: 745 Seventh Avenue, New York, New York, United States. Speakers: Karine Kleinhaus, Divisional Vice President of North- America.

Pluristem Therapeutics Inc. Announces Amendment to the Amended and Restated Articles of Incorporation

Pluristem Therapeutics Inc. at its annual meeting of stockholders on May 22, 2014, approved amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:US $2.93 USD 0.00

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.63 USD -0.11
Athersys Inc $1.69 USD -0.04
Cardica Inc $1.15 USD -0.01
Cerus Corp $4.02 USD +0.19
Cytori Therapeutics Inc $2.21 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 505.9x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 365.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at